• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jasper Therapeutics, Inc. - Class A Common Stock (NQ:JSPR)

2.495 +0.075 (+3.10%)
Streaming Delayed Price Updated: 12:56 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 135,349
Open 2.430
Bid (Size) 2.490 (3)
Ask (Size) 2.500 (10)
Prev. Close 2.420
Today's Range 2.400 - 2.528
52wk Range 2.215 - 26.05
Shares Outstanding 736,213
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPR
October 01, 2025
From The Rosen Law Firm PA
Via GlobeNewswire
JASPER CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors a Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. and Encourages Investors to Contact the Firm
September 30, 2025
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
-88.2%
-88.2%
1 Month
-9.6%
-9.6%
3 Month
-63.1%
-63.1%
6 Month
-37.8%
-37.8%
1 Year
-85.3%
-85.3%

More News

Read More
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
September 30, 2025
Via NewMediaWire
Topics Lawsuit
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
September 30, 2025
Via TheNewswire.com
Topics Lawsuit
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
September 30, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
Deadline Alert: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
September 29, 2025
From Glancy Prongay & Murray LLP
Via Business Wire
Deadline Approaching: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
September 26, 2025
From Law Offices of Howard G. Smith
Via Business Wire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPR
September 25, 2025
From The Rosen Law Firm PA
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Encourages Jasper Therapeutics, Inc. (JSPR) Shareholders To Inquire About Securities Fraud Class Action
September 25, 2025
From Glancy Prongay & Murray LLP
Via Business Wire
Faruqi & Faruqi Reminds Jasper Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 18 , 2025 - JSPR
September 25, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
September 24, 2025
Via Benzinga
Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers – JSPR
September 24, 2025
From Pomerantz LLP
Via GlobeNewswire
Law Offices of Howard G. Smith Encourages Jasper Therapeutics, Inc. (JSPR) Investors To Inquire About Securities Fraud Class Action
September 24, 2025
From Law Offices of Howard G. Smith
Via Business Wire
Law Offices of Frank R. Cruz Encourages Jasper Therapeutics, Inc. (JSPR) Investors To Inquire About Securities Fraud Class Action
September 24, 2025
From The Law Offices of Frank R. Cruz
Via Business Wire
JASPER ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. and Encourages Investors to Contact the Firm
September 23, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
Securities Fraud Investigation Into Jasper Therapeutics, Inc. (JSPR) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
September 23, 2025
From Glancy Prongay & Murray LLP
Via Business Wire
Jasper Therapeutics, Inc. (JSPR) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
September 23, 2025
From Law Offices of Howard G. Smith
Via Business Wire
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – JSPR
September 22, 2025
From DJS Law Group
Via Business Wire
Securities Fraud Investigation Into Jasper Therapeutics, Inc. (JSPR) Announced – Investors Who Lost Money Urged to Contact the Law Offices of Frank R. Cruz
September 22, 2025
From The Law Offices of Frank R. Cruz
Via Business Wire
JSPR Stockholder Alert: Robbins LLP Reminds Investors of the Securities Fraud Class Action Against Jasper Therapeutics, Inc.
September 22, 2025
From Robbins LLP
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
September 22, 2025
From Faruqi & Faruqi, LLP
Via Business Wire
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
September 21, 2025
From The Schall Law Firm
Via Business Wire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPR
September 21, 2025
From The Rosen Law Firm PA
Via GlobeNewswire
Rosen Law Firm Urges Jasper Therapeutics, Inc. (NASDAQ: JSPR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
September 20, 2025
From The Rosen Law Firm, P.A.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
September 19, 2025
Via Benzinga

Frequently Asked Questions

Is Jasper Therapeutics, Inc. - Class A Common Stock publicly traded?
Yes, Jasper Therapeutics, Inc. - Class A Common Stock is publicly traded.
What exchange does Jasper Therapeutics, Inc. - Class A Common Stock trade on?
Jasper Therapeutics, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Jasper Therapeutics, Inc. - Class A Common Stock?
The ticker symbol for Jasper Therapeutics, Inc. - Class A Common Stock is JSPR on the Nasdaq Stock Market
What is the current price of Jasper Therapeutics, Inc. - Class A Common Stock?
The current price of Jasper Therapeutics, Inc. - Class A Common Stock is 2.495
When was Jasper Therapeutics, Inc. - Class A Common Stock last traded?
The last trade of Jasper Therapeutics, Inc. - Class A Common Stock was at 10/03/25 12:56 PM ET
What is the market capitalization of Jasper Therapeutics, Inc. - Class A Common Stock?
The market capitalization of Jasper Therapeutics, Inc. - Class A Common Stock is 1.84M
How many shares of Jasper Therapeutics, Inc. - Class A Common Stock are outstanding?
Jasper Therapeutics, Inc. - Class A Common Stock has 2M shares outstanding.
Recent Quotes
View More
Symbol Price Change (%)
GOOG  246.94
+0.51 (0.21%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap